systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-719Research ArticleСТАТЬИARTICLESПрименение неселективного антагониста рецепторов эндотелина бозентана у больных идиопатической легочной гипертензией: первый российский опыт и взгляд в будущееМартынюкТ. В.noemail@neicon.ruАрхиповаО. А.noemail@neicon.ruКобальЕ. А.noemail@neicon.ruЕруслановаК. А.noemail@neicon.ruДаниловН. М.noemail@neicon.ruЧазоваИ. Е.noemail@neicon.ruИнститут клинической кардиологии им. А.Л.Мясникова ФГУ РКНПК Минздравсоцразвития РФ, МоскваRussian Federation201109022023845157Copyright © Мартынюк Т.В., Архипова О.А., Кобаль Е.А., Ерусланова К.А., Данилов Н.М., Чазова И.Е., 20232023Мартынюк Т.В., Архипова О.А., Кобаль Е.А., Ерусланова К.А., Данилов Н.М., Чазова И.Е.Мартынюк Т.В., Архипова О.А., Кобаль Е.А., Ерусланова К.А., Данилов Н.М., Чазова И.Е.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/719ReferencesНациональные рекомендации ВНОК по диагностике и лечению легочной гипертензии. 2007.Национальные рекомендации ВНОК по диагностике и лечению легочной гипертензии. 2007.Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the ECS and ERS, endorsed by the ISHLT. Eur Heart J 2009; 30: 2493-537.Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the ECS and ERS, endorsed by the ISHLT. Eur Heart J 2009; 30: 2493-537.Galie N, Manes A, Branzi A. The endothelin system in pulmonary hypertension. Cardiovasc Res 2004; 61: 227-37.Galie N, Manes A, Branzi A. The endothelin system in pulmonary hypertension. Cardiovasc Res 2004; 61: 227-37.McLaughlin VV, Sitbon O, Rubin L et al. The effect of first-line Bosentan on survival of patients with primary pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: A442.McLaughlin VV, Sitbon O, Rubin L et al. The effect of first-line Bosentan on survival of patients with primary pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: A442.Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008; 31: 407-15.Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008; 31: 407-15.Rubin LJ, Galie N, Badesch DB et al. Ambrisentan improves exercise capacity and clinical measures in pulmonary arterial hypertension. Am J Crit Care Med 2004; 169: A210.Rubin LJ, Galie N, Badesch DB et al. Ambrisentan improves exercise capacity and clinical measures in pulmonary arterial hypertension. Am J Crit Care Med 2004; 169: A210.Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl. J Med 2002; 346: 896-903.Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl. J Med 2002; 346: 896-903.Galie N, Rubin LJ, Hoeper MM et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-100.Galie N, Rubin LJ, Hoeper MM et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-100.Sitbon O, Badesch DB, Channick RN. Effects of the dual endothelin- receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124: 247-54.Sitbon O, Badesch DB, Channick RN. Effects of the dual endothelin- receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124: 247-54.Provencher S et al. Long-term Outcome with First-line Bosentan Therapy in Idiopathic Pulmonary Arterial Hypertension. Eur Heart J 2006; 27: 589-95.Provencher S et al. Long-term Outcome with First-line Bosentan Therapy in Idiopathic Pulmonary Arterial Hypertension. Eur Heart J 2006; 27: 589-95.
The authors declare that there are no conflicts of interest present.